Cargando…
P884: POTENTIAL BENEFIT OF POST-TRANSPLANT DOXYCYCLINE IN AL ACHIEVING HEMATOLOGICAL RESPONSE AFTER AUTOLOGOUS STEM CELL TRANSPLANT – LONG TERM FOLLOW UP
Autores principales: | Abdallah, N., Dispenzieri, A., Muchtar, E., Buadi, F., Kapoor, P., Lacy, M., Hwa, Y., Fonder, A., Hobbs, M., Hayman, S., Leung, N., Dingli, D., Go, R., Lin, Y., Gonsalves, W., Binder, M., Kourelis, T., Warsame, R., Kyle, R., Rajkumar, S., Gertz, M., Kumar, S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430486/ http://dx.doi.org/10.1097/01.HS9.0000846412.15297.aa |
Ejemplares similares
-
Daratumumab, carfilzomib, and pomalidomide for the treatment of POEMS syndrome: The Mayo Clinic Experience
por: Vaxman, I., et al.
Publicado: (2023) -
Outcomes among newly diagnosed AL amyloidosis patients with a very high NT-proBNP: implications for trial design
por: Vaxman, I., et al.
Publicado: (2021) -
Long-term outcomes of allogeneic stem cell transplant in multiple myeloma
por: Schmidt, Walker M., et al.
Publicado: (2023) -
P966: DARATUMUMAB, CARFILZOMIB, POMALIDOMIDE AND ELOTUZUMAB FOR THE TREATMENT OF POEMS SYNDROME- THE MAYO CLINIC EXPERIENCE
por: Vaxman, I., et al.
Publicado: (2022) -
“Real-life” data of the efficacy and safety of belantamab mafodotin in relapsed multiple myeloma—the Mayo Clinic experience
por: Vaxman, I., et al.
Publicado: (2021)